Publications 2017

Lingscheid T, Kurth F, Clerinx J, Marocco S, Trevino B, Schunk M, Muñoz J, Gjørup IE, Jelinek T, Develoux M, Fry G, Jänisch T, Schmid ML, Bouchaud O, Puente S, Zammarchi L, Mørch K, Björkman A, Siikamäki H, Neumayr A, Nielsen H, Hellgren U, Paul M, Calleri G, Kosina P et al. (2017)
Schistosomiasis in European Travelers and Migrants: Analysis of 14 Years TropNet Surveillance Data
Am J Trop Med Hyg, 97 (2), 567-574
DOI 10.4269/ajtmh.17-0034, PubMed 28722637

Publications 2015

Myrvang B (2015)
Manson's tropical diseases
Tidsskr. Nor. Laegeforen., 135 (2), 158
DOI 10.4045/tidsskr.14.1289

Publications 2012

Mørch K, Myrvang B (2012)
Treatment of malaria in Norway
Tidsskr Nor Laegeforen, 132 (6), 664-7
DOI 10.4045/tidsskr.11.0589, PubMed 22456148

Publications 2010

Behrens RH, Carroll B, Hellgren U, Visser LG, Siikamäki H, Vestergaard LS, Calleri G, Jänisch T, Myrvang B, Gascon J, Hatz C (2010)
The incidence of malaria in travellers to South-East Asia: is local malaria transmission a useful risk indicator?
Malar J, 9, 266
DOI 10.1186/1475-2875-9-266, PubMed 20920352

Myrvang B (2010)
[A fifth plasmodium that can cause malaria]
Tidsskr Nor Laegeforen, 130 (3), 282-3
DOI 10.4045/tidsskr.09.0554, PubMed 20160773

Publications 2009

Berhe N, Myrvang B, Gundersen SG (2009)
Gastro-intestinal symptoms associated with intense Schistosoma mansoni infection affect class-attentiveness of schoolchildren in Ethiopia
Acta Trop, 110 (1), 52-6
DOI 10.1016/j.actatropica.2009.01.007, PubMed 19283896

Publications 2008

Berhe N, Myrvang B, Gundersen SG (2008)
Reversibility of schistosomal periportal thickening/fibrosis after praziquantel therapy: a twenty-six month follow-up study in Ethiopia
Am J Trop Med Hyg, 78 (2), 228-34
DOI 10.4269/ajtmh.2008.78.228, PubMed 18256420

Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group (2008)
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
Hepatology, 47 (1), 35-42
DOI 10.1002/hep.21975, PubMed 17975791

Jelinek T, Schade Larsen C, Siikamäki H, Myrvang B, Chiodini P, Gascon J, Visser L, Kapaun A, Just-Nübling G (2008)
European cluster of imported falciparum malaria from Gambia
Euro Surveill, 13 (51)
PubMed 19094917

Newport MJ, Myrvang B (2008)
Proceedings of a joint meeting between the Norwegian Society of Infectious Diseases and the Royal Society of Tropical Medicine and Hygiene, Oslo, 20 June 2008
Trans R Soc Trop Med Hyg, 103 (4), 321-4
DOI 10.1016/j.trstmh.2008.11.010, PubMed 19111872

Publications 2007

Behrens RH, Carroll B, Beran J, Bouchaud O, Hellgren U, Hatz C, Jelinek T, Legros F, Mühlberger N, Myrvang B, Siikamäki H, Visser L, TropNetEurop (2007)
The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis?
Malar J, 6, 114
DOI 10.1186/1475-2875-6-114, PubMed 17716367

Berhe N, Halvorsen BL, Gundersen TE, Myrvang B, Gundersen SG, Blomhoff R (2007)
Reduced serum concentrations of retinol and alpha-tocopherol and high concentrations of hydroperoxides are associated with community levels of S. mansoni infection and schistosomal periportal fibrosis in Ethiopian school children
Am J Trop Med Hyg, 76 (5), 943-9
DOI 10.4269/ajtmh.2007.76.943, PubMed 17488920

Berhe N, Myrvang B, Gundersen SG (2007)
Intensity of Schistosoma mansoni, hepatitis B, age, and sex predict levels of hepatic periportal thickening/fibrosis (PPT/F): a large-scale community-based study in Ethiopia
Am J Trop Med Hyg, 77 (6), 1079-86
DOI 10.4269/ajtmh.2007.77.1079, PubMed 18165526

Myrvang B (2007)
Plassen kirke 100 år: jubileumsbok om kirke og grendefolk
Trysil-forl, [Nybergsund], 221 s.
BIBSYS 071763147, ISBN 978-82-91352-63-3

Storla DG, Rahim Z, Islam MA, Plettner S, Begum V, Myrvang B, Bjune G, Rønnild E, Dahle UR, Mannsåker T (2007)
Drug resistance of Mycobacterium tuberculosis in the Sunamganj District of Bangladesh
Scand J Infect Dis, 39 (2), 142-5
DOI 10.1080/00365540600951242, PubMed 17366031

Publications 2006

Damås JK, Jensenius M, Ueland T, Otterdal K, Yndestad A, Frøland SS, Rolain JM, Myrvang B, Raoult D, Aukrust P (2006)
Increased levels of soluble CD40L in African tick bite fever: possible involvement of TLRs in the pathogenic interaction between Rickettsia africae, endothelial cells, and platelets
J Immunol, 177 (4), 2699-706
DOI 10.4049/jimmunol.177.4.2699, PubMed 16888032

Gjeruldsen S, Loge JH, Myrvang B, Opjordsmoen S (2006)
Drug addiction in hepatitis C patients leads to a lower quality of life
Nord J Psychiatry, 60 (2), 157-61
DOI 10.1080/08039480600583639, PubMed 16635936

Jensenius M, Fournier PE, Fladby T, Hellum KB, Hagen T, Priø T, Christiansen MS, Vene S, Raoult D, Myrvang B (2006)
Sub-acute neuropathy in patients with African tick bite fever
Scand J Infect Dis, 38 (2), 114-8
DOI 10.1080/00365540500321579, PubMed 16449002

Nygård K, Brantsaeter A, Feruglio S, Ravn J, Dotevall L, Hasle G, Myrvang B (2006)
[Histoplasmosis among travellers to Central America]
Tidsskr Nor Laegeforen, 126 (21), 2838-42
PubMed 17086244

Storla DG, Rahim Z, Islam MA, Plettner S, Begum V, Mannsaaker T, Myrvang B, Bjune G, Dahle UR (2006)
Heterogeneity of Mycobacterium tuberculosis isolates in Sunamganj District, Bangladesh
Scand J Infect Dis, 38 (8), 593-6
DOI 10.1080/00365540600606465, PubMed 16857601

Publications 2005

Jensenius M, Flaegstad T, Stenstad T, Gjølberg T, Vlatkovic L, Schjøth-Iversen L, Berild D, Bordmann G, Myrvang B (2005)
Fascioliasis imported to Norway
Scand J Infect Dis, 37 (6-7), 534-7
DOI 10.1080/00365540510034518, PubMed 16012024

Jensenius M, Pretorius AM, Clarke F, Myrvang B (2005)
Repellent efficacy of four commercial DEET lotions against Amblyomma hebraeum (Acari: Ixodidae), the principal vector of Rickettsia africae in southern Africa
Trans R Soc Trop Med Hyg, 99 (9), 708-11
DOI 10.1016/j.trstmh.2005.01.006, PubMed 15993907

Publications 2004

Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
Hepatology, 40 (6), 1260-5
DOI 10.1002/hep.20467, PubMed 15558712

Dalgard O, Bjøro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H (2004)
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study
In Hepatology, Wiley, New York, 40(2004)6, S. 1260-5
BIBSYS 051781174

Jelinek T, Myrvang B (2004)
Surveillance of imported infectious diseases in Europe: report from the 4th TropNetEurop workshop
Acta Trop, 91 (1), 47-51
DOI 10.1016/j.actatropica.2004.02.007, PubMed 15158688

Jensenius M, Fournier PE, Vene S, Ringertz SH, Myrvang B, Raoult D (2004)
Comparison of immunofluorescence, Western blotting, and cross-adsorption assays for diagnosis of African tick bite fever
Clin Diagn Lab Immunol, 11 (4), 786-8
DOI 10.1128/CDLI.11.4.786-788.2004, PubMed 15242958

Jensenius M, Fournier PE, Vene S, Ringertz SH, Myrvang B, Raoult D (2004)
Comparison of immunofluorescence, western blotting and cross-adsorption assays for diagnosis of African tick bite fever
In Clinical and diagnostic laboratory immunology, American Society for Microbiology, Washington, 11(2004)4, S. 786-88
BIBSYS 051805006

Mühlberger N, Jelinek T, Gascon J, Probst M, Zoller T, Schunk M, Beran J, Gjørup I, Behrens RH, Clerinx J, Björkman A, McWhinney P, Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid ML, Myrvang B, Holthoff-Stich ML, Laferl H, Hatz C, Kollaritsch H, Kapaun A, Knobloch J et al. (2004)
Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop
Malar J, 3, 5
DOI 10.1186/1475-2875-3-5, PubMed 15003128

Rogne Gjeruldsen S, Myrvang B, Opjordsmoen S (2004)
Criminality in drug addicts: a follow-up study over 25 years
Eur Addict Res, 10 (2), 49-55
DOI 10.1159/000076113, PubMed 15004447

Publications 2003

Dalgard O, Skaug K, Ritland S, Myrvang B, Hellum K, Bjøro K, Bell H (2003)
Short treatment (14 weeks) with pegylated interferon alpha-2B and ribavirin for the treatment of hepatitis C genotype 2/3 infection
In Journal of hepatology, Munksgaard, København, 38(2003)Suppl 2, s.134-5
BIBSYS 041707680

Gjeruldsen S, Myrvang B, Opjordsmoen S (2003)
Risk factors for drug addiction and its outcome. A follow-up study over 25 years
Nord J Psychiatry, 57 (5), 373-6
DOI 10.1080/08039480310002714, PubMed 14522611

Gjeruldsen SR, Myrvang B, Opjordsmoen S (2003)
A 25-year follow-up study of drug addicts hospitalised for acute hepatitis: present and past morbidity
Eur Addict Res, 9 (2), 80-6
DOI 10.1159/000068805, PubMed 12644734

Grobusch MP, Mühlberger N, Jelinek T, Bisoffi Z, Corachán M, Harms G, Matteelli A, Fry G, Hatz C, Gjørup I, Schmid ML, Knobloch J, Puente S, Bronner U, Kapaun A, Clerinx J, Nielsen LN, Fleischer K, Beran J, da Cunha S, Schulze M, Myrvang B, Hellgren U (2003)
Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop
J Travel Med, 10 (3), 164-9
DOI 10.2310/7060.2003.35759, PubMed 12757691

Jensenius M, Fournier PE, Hellum KB, Wesslen L, Caruso G, Prio T, Lohne K, Vene S, Raoult D, Myrvang B (2003)
Sequential changes in hematologic and biochemical parameters in African tick bite fever
In Clinical microbiology and infection, Decker Europe, London, 9(2003)7, s.678-83
BIBSYS 041718410

Jensenius M, Fournier PE, Hellum KB, Wesslén L, Caruso G, Priø T, Løhne K, Vene S, Raoult D, Myrvang B (2003)
Sequential changes in hematologic and biochemical parameters in African tick bite fever
Clin Microbiol Infect, 9 (7), 678-83
DOI 10.1046/j.1469-0691.2003.00713.x, PubMed 12925109

Jensenius M, Fournier PE, Kelly P, Myrvang B, Raoult D (2003)
African tick bite fever
Lancet Infect Dis, 3 (9), 557-64
DOI 10.1016/s1473-3099(03)00739-4, PubMed 12954562

Jensenius M, Fournier PE, Kelly P, Myrvang B, Raoult D (2003)
African tick bite fever
In Lancet infectious diseases, Elsevier Science ; Lancet publ., New York, NY, 3(2003)9, s.557-64
BIBSYS 041718445

Jensenius M, Fournier PE, Vene S, Hoel T, Hasle G, Henriksen AZ, Hellum KB, Raoult D, Myrvang B (2003)
African tick bite fever in travelers to rural sub-Equatorial Africa
In Clinical infectious diseases, University of Chicago Press, Chicago, 36(2003)11, s.1411-7
BIBSYS 041718356

Jensenius M, Fournier PE, Vene S, Hoel T, Hasle G, Henriksen AZ, Hellum KB, Raoult D, Myrvang B, Norwegian African Tick Bite Fever Study Group (2003)
African tick bite fever in travelers to rural sub-Equatorial Africa
Clin Infect Dis, 36 (11), 1411-7
DOI 10.1086/375083, PubMed 12766836

Jensenius M, Ueland T, Fournier PE, Brosstad F, Stylianou E, Vene S, Myrvang B, Raoult D, Aukrust P (2003)
Systemic inflammatory responses in African tick-bite fever
J Infect Dis, 187 (8), 1332-6
DOI 10.1086/368415, PubMed 12696016

Jensenius M, Ueland T, Fournier PE, Brosstad F, Stylianou E, Vene S, Myrvang B, Raoult D, Aukrust P (2003)
Systematic inflammatory responses in African tick-bite fever
In Journal of infectious diseases, University of Chicago Press, Chicago, 187(2003)8, s.1332-6
BIBSYS 041718305

Mühlberger N, Jelinek T, Behrens RH, Gjørup I, Coulaud JP, Clerinx J, Puente S, Burchard G, Gascon J, Grobusch MP, Weitzel T, Zoller T, Kollaritsch H, Beran J, Iversen J, Hatz C, Schmid ML, Björkman A, Fleischer K, Bisoffi Z, Guggemos W, Knobloch J, Matteelli A, Schulze MH, Laferl H et al. (2003)
Age as a risk factor for severe manifestations and fatal outcome of falciparum malaria in European patients: observations from TropNetEurop and SIMPID Surveillance Data
Clin Infect Dis, 36 (8), 990-5
DOI 10.1086/374224, PubMed 12684911

Publications 2002

Bell H, Dalgard O, Bjøro K, Hellum KB, Myrvang B (2002)
[Treatment of chronic hepatitis C]
Tidsskr Nor Laegeforen, 122 (9), 926-8
PubMed 12082838

Bjøro K, Bell H, Hellum K, Skaug K, Raknerud N, Sandvei P, Døskeland B, Mæland A, Lund-Tønnesen S, Myrvang B (2002)
Effect of combined interferon-alpha induction therapy andribavirin on chronic hepatitis C virus infection: a randomized multicentre study
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 2, s. 226-232
BIBSYS 031205933

Bjøro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Døskeland B, Maeland A, Lund-Tønnesen S, Myrvang B (2002)
Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study
Scand J Gastroenterol, 37 (2), 226-32
DOI 10.1080/003655202753416920, PubMed 11843062

Bjøro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Storseth S, Ritland S, Lund-Tønnesen S, Bucher A, Hellum K (2002)
Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study
In Scandinavian journal of gastroenterology, Taylor & Francis, Basingstoke, 37(2002)nr 3, s. 344-349
BIBSYS 03120550x

Bjøro K, Bell H, Myrvang B, Skaug K, Raknerud N, Sandvei P, Størseth S, Ritland S, Lund-Tønnesen S, Bucher A, Hellum KB (2002)
Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study
Scand J Gastroenterol, 37 (3), 344-9
DOI 10.1080/003655202317284264, PubMed 11916198

Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (2002)
Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy
J Intern Med, 251 (5), 400-6
DOI 10.1046/j.1365-2796.2002.00974.x, PubMed 11982739

Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E, Bell H (2002)
Thyroid dysfunction during treatment of chronic hepatitisC with interferon alpha: no association with wither dosage or efficacy of therapy
In Journal of internal medicine, Blackwell Scientific Publ., Oxford, 251(2002)nr 5, s. 400-406
BIBSYS 031206328

Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H (2002)
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
In European addiction research, Karger, Basel, 8(2002)nr 1, s. 45-49
BIBSYS 031206530

Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, Bell H, Construct Group (2002)
Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up
Eur Addict Res, 8 (1), 45-9
DOI 10.1159/000049487, PubMed 11818693

Distante S, Bjøro K, Hellum K, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H (2002)
Raised serum ferritin predicts non-response to interferonand ribavirin treatment in patients with chronic hepatitis C-infection
In Journal of hepatology, Munksgaard, København, 36(2002)Suppl 1, s. 233
BIBSYS 03142631x

Distante S, Bjøro K, Hellum KB, Myrvang B, Berg JP, Skaug K, Raknerud N, Bell H (2002)
Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection
Liver, 22 (3), 269-75
DOI 10.1046/j.0106-9543.2002.01672.x, PubMed 12100578

Dunlop O, Bjørklund R, Bruun JN, Evensen R, Goplen AK, Liestøl K, Sannes M, Maehlen J, Myrvang B (2002)
Early psychomotor slowing predicts the development of HIV dementia and autopsy-verified HIV encephalitis
Acta Neurol Scand, 105 (4), 270-5
DOI 10.1034/j.1600-0404.2002.9o188.x, PubMed 12004769

Gjeruldsen S, Myrvang B (2002)
Hepatitis B virus infection in drug addicts: no acute fatalities, no chronicity and could have benefits
APMIS, 110 (9), 620-4
DOI 10.1034/j.1600-0463.2002.1100904.x, PubMed 12529014

Jelinek T, Mühlberger N, Harms G, Corachán M, Grobusch MP, Knobloch J, Bronner U, Laferl H, Kapaun A, Bisoffi Z, Clerinx J, Puente S, Fry G, Schulze M, Hellgren U, Gjørup I, Chalupa P, Hatz C, Matteelli A, Schmid M, Nielsen LN, da Cunha S, Atouguia J, Myrvang B, Fleischer K et al. (2002)
Epidemiology and clinical features of imported dengue fever in Europe: sentinel surveillance data from TropNetEurop
Clin Infect Dis, 35 (9), 1047-52
DOI 10.1086/342906, PubMed 12384837

Jensenius M, Hoel T, Raoult D, Fournier PE, Kjelshus H, Bruu AL, Myrvang B (2002)
Seroepidemiology of Rickettsia africae infection in Norwegian travellers to rural Africa
Scand J Infect Dis, 34 (2), 93-6
DOI 10.1080/00365540110077029, PubMed 11928860

Jensenius M, Hoel T, Raoult D, Fournier PE, Kjelshus H, Bruu AL, Myrvang B (2002)
Seroepidemiology of Rickettsia africae infection in Norwegian travellers to rural Africa
In Scandinavian journal of infectious diseases, Taylor & Francis, Basingstoke, 34(2002)2, s. 93-6
BIBSYS 031424511

Myrvang B, von der Lippe B (2002)
[African trypanosomiasis--a rare imported disease]
Tidsskr Nor Laegeforen, 122 (1), 33-4
PubMed 11851292

Strand EA, Strand ØA, Hellum KB, Smith-Erichsen N, Myrvang B (2002)
[A young, stuporous and afebrile man with icterus and nosebleed]
Tidsskr Nor Laegeforen, 122 (6), 619-23
PubMed 11998715

Publications 2001

Gjeruldsen S, Abdelnoor M, Opjordsmoen S, Myrvang B (2001)
Death rates and causes of death in cohorts of serum hepatitis patients followed up for more than 20 years
Epidemiol Infect, 126 (1), 89-96
DOI 10.1017/s0950268801005064, PubMed 11293686

Publications 2000

Bjøro K, Bell H, Hellum K, Myrvang B, Skaug K (2000)
Randomized trial of IFN-A induction and ribavirin vs standard IFN-A and ribavirin for chronic HCV in perviously untreated patients
In Hepatology, Wiley, New York, 32(2000)nr 4 del 2, s.317A
BIBSYS 010838090

Brubakk O, Myrvang B (2000)
[Non-practical guidelines?]
Tidsskr Nor Laegeforen, 120 (26), 3196
PubMed 11109372

Dalgard O, Bjøro K, Myrvang B, Hellum K, Skaug K, Gutigard B, Bell H (2000)
Long-term follow-up after treatment of chronic hepatitis C with interferon-A: Reinfection in injecting drug users
In Hepatology, Wiley, New York, 32(2000)nr 4 del 2, s.359A
BIBSYS 01080109x

Liestøl K, Kvittingen EA, Rootwelt H, Dunlop O, Goplen AK, Pedersen JC, Brorson SH, Børresen-Dale AL, Myrvang B, Maehlen J (2000)
Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome
Cancer Detect Prev, 24 (5), 496-9
PubMed 11129992

Myrvang B (2000)
[Malaria in Norway--diagnosis, treatment and prevention]
Tidsskr Nor Laegeforen, 120 (14), 1648-52
PubMed 10901075

Myrvang B, Godal T (2000)
[WHO's malaria program Roll Back Malaria]
Tidsskr Nor Laegeforen, 120 (14), 1661-4
PubMed 10901078

Mørk C, Kalgaard OM, Myrvang B, Kvernebo K (2000)
Erythromelalgia in a patient with AIDS
J Eur Acad Dermatol Venereol, 14 (6), 498-500
DOI 10.1046/j.1468-3083.2000.00145.x, PubMed 11444274

Rønning EJ, Myrvang B, Jensenius M (2000)
[Falciparum malaria in Oslo and Akerhus]
Tidsskr Nor Laegeforen, 120 (14), 1658-60
PubMed 10901077

Rønning EJ, Myrvang B, Jensenius M (2000)
Falciparummalaria i Oslo og Akershus
In Tidsskrift for Den norske legeforening, Foreningen, Oslo, 120(2000)nr. 14, S. 1658-1660
BIBSYS 010781358

Publications 1999

Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P (1999)
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group
Scand J Gastroenterol, 34 (2), 194-8
DOI 10.1080/00365529950173087, PubMed 10192200

Hem E, Small T, Opjordsmoen S, Myrvang B (1999)
[Neurosyphilis--still a relevant differential diagnosis]
Tidsskr Nor Laegeforen, 119 (17), 2469-71
PubMed 10425898

Jensenius M, Hasle G, Henriksen AZ, Vene S, Raoult D, Bruu AL, Myrvang B (1999)
African tick-bite fever imported into Norway: presentation of 8 cases
Scand J Infect Dis, 31 (2), 131-3
DOI 10.1080/003655499750006155, PubMed 10447320

Jensenius M, Rønning EJ, Blystad H, Bjørneklett A, Hellum KB, Bucher A, Håheim LL, Myrvang B (1999)
Low frequency of complications in imported falciparum malaria: a review of 222 cases in south-eastern Norway
Scand J Infect Dis, 31 (1), 73-8
DOI 10.1080/00365549950161925, PubMed 10381222

Tangen JM, Berentsen S, Dahl IM, Ly B, Myrvang B (1999)
[Empirical antibiotic treatment of patients with acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 119 (1), 35-8
PubMed 10025202

Publications 1998

Jarvis LM, Bell H, Simmonds P, Hawkins A, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K (1998)
The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia. The CONSTRUCT Group
Scand J Gastroenterol, 33 (2), 195-200
DOI 10.1080/00365529850166941, PubMed 9517532

Jensenius M, Myrvang B (1998)
[Imported fever]
Tidsskr Nor Laegeforen, 118 (3), 402-6
PubMed 9499729

Jensenius M, Myrvang B (1998)
[Imported fever. A diagnostic challenge]
Nord Med, 113 (4), 107-11
PubMed 9579092

Jensenius M, Myrvang B, Størvold G, Bucher A, Hellum KB, Bruu AL (1998)
Herpes simplex virus type 2 DNA detected in cerebrospinal fluid of 9 patients with Mollaret's meningitis
Acta Neurol Scand, 98 (3), 209-12
DOI 10.1111/j.1600-0404.1998.tb07296.x, PubMed 9786620

Lundin KE, Selbekk BH, Myrvang B, Løberg EM (1998)
[Cytomegalovirus as the cause of toxic dilatation of the colon]
Tidsskr Nor Laegeforen, 118 (21), 3277-9
PubMed 9772815

Publications 1997

Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Gutigard BG, Skjaerven R, Prescott LE, Simmonds P (1997)
Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group
Scand J Infect Dis, 29 (1), 17-22
DOI 10.3109/00365549709008658, PubMed 9112292

Dunlop O, Goplen AK, Liestøl K, Myrvang B, Rootwelt H, Christophersen B, Kvittingen EA, Maehlen J (1997)
HIV dementia and apolipoprotein E
Acta Neurol Scand, 95 (5), 315-8
DOI 10.1111/j.1600-0404.1997.tb00217.x, PubMed 9188909

Gundersen SG, Rostrup M, von der Lippe E, Platou ES, Myrvang B, Edwards G (1997)
Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation
Scand J Infect Dis, 29 (2), 207-8
DOI 10.3109/00365549709035889, PubMed 9181664

Jensenius M, Myrvang B, Størvold G (1997)
[Serous meningitis associated with primary genital herpes infection]
Tidsskr Nor Laegeforen, 117 (16), 2316-8
PubMed 9265274

Jenseuius M, Myrvang B, Størvold G (1997)
[Mollaret meningitis. Is the riddle finally solved?]
Tidsskr Nor Laegeforen, 117 (16), 2319-21
PubMed 9265275

Myrvang B (1997)
[Malaria in Norway]
Tidsskr Nor Laegeforen, 117 (7), 984-5
PubMed 9103014

Publications 1996

Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Prescott L, Simmonds P (1996)
Prevalence of hepatitis C genotypes among patients with chronic hepatitis C in Norway. Construct Group
Scand J Infect Dis, 28 (4), 357-9
DOI 10.3109/00365549609037919, PubMed 8893398

Dunlop O, Rootwelt V, Sannes M, Goplen AK, Abdelnoor M, Skaug K, Baklien K, Skar A, Melby K, Myrvang B, Bruun JN (1996)
Risk of toxoplasmic encephalitis in AIDS patients: indications for prophylaxis
Scand J Infect Dis, 28 (1), 71-3
DOI 10.3109/00365549609027153, PubMed 9122637

Schrumpf E, Bjøro K, Bell H, Harthug S, Hellum KB, Myrvang B, Maeland A, Ritland S (1996)
[Treatment of hepatitis C]
Tidsskr Nor Laegeforen, 116 (15), 1792-4
PubMed 8693463

Publications 1995

Gundersen SG, Myrvang B (1995)
[Specific intracranial infections]
Tidsskr Nor Laegeforen, 115 (19), 2434
PubMed 7667862

Myrvang B (1995)
Mycobacterial infections in Norway
Scand J Infect Dis Suppl, 98, 12-4
PubMed 8867170

Myrvang B (1995)
Mycobacterial infections in Norway
Scand. J. Infect. Dis. (98), 12-14

Publications 1993

Dunlop O, Bjørklund R, Abdelnoor M, Myrvang B (1993)
Total reaction time: a new approach in early HIV encephalopathy?
Acta Neurol Scand, 88 (5), 344-8
DOI 10.1111/j.1600-0404.1993.tb05355.x, PubMed 8296533

Publications 1992

Dunlop O, Bjørklund RA, Abdelnoor M, Myrvang B (1992)
Five different tests of reaction time evaluated in HIV seropositive men
Acta Neurol Scand, 86 (3), 260-6
DOI 10.1111/j.1600-0404.1992.tb05082.x, PubMed 1414244

Dunlop O, Myrvang B, Bjørklund R (1992)
Neuropsychological tests in HIV
Neurology, 42 (10), 2055-6
DOI 10.1212/wnl.42.10.2055-c, PubMed 1407598

Publications 1991

Dunlop O, Bruun JN, Myrvang B, Fagerhol MK (1991)
Calprotectin in cerebrospinal fluid of the HIV infected: a diagnostic marker of opportunistic central nervous system infection?
Scand J Infect Dis, 23 (6), 687-9
DOI 10.3109/00365549109024294, PubMed 1815329

Midtvedt K, Myrvang B (1991)
[Antibiotic prevention in permanent pacemaker implantation in Norway]
Tidsskr Nor Laegeforen, 111 (9), 1106-7
PubMed 2024255

Publications 1983

Linnestad P, Myrvang B, Ritland S, Bergan A, Valnes K, Holst JJ (1983)
[Glucagon producing tumors of the pancreas. A case report and literature review]
Tidsskr Nor Laegeforen, 103 (22), 1520-2
PubMed 6314588

Myrvang B (1983)
[Gammaglobulin replacement therapy - indications and realization]
Tidsskr Nor Laegeforen, 103 (3), 219-22
PubMed 6189243

Myrvang B (1983)
[What role does the immune apparatus play in the defense against fungal infections?]
Tidsskr Nor Laegeforen, 103 (3), 182-3
PubMed 6845311

Myrvang B (1983)
[Skin tests as a diagnostic aid in infectious diseases]
Tidsskr Nor Laegeforen, 103 (3), 201-3
PubMed 6845321

Myrvang B (1983)
[Immunological studies in the diagnosis of imported parasitic diseases]
Tidsskr Nor Laegeforen, 103 (3), 211-3
PubMed 6845324

Myrvang B (1983)
[Pneumococcal vaccine - characteristics and indications]
Tidsskr Nor Laegeforen, 103 (3), 226-8
PubMed 6845327

Publications 1982

Melsom R, Harboe M, Myrvang B, Godal T, Belehu A (1982)
Immunoglobulin class specific antibodies to M. leprae in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy
Clin Exp Immunol, 47 (2), 225-33
PubMed 7042137

Publications 1977

Thoresen U, Myrvang B (1977)
Trollmann med tømmene
Aschehoug, Oslo, 159 s.,[8] pl.
BIBSYS 950108065, ISBN 82-03-09350-7

Publications 1975

Myrvang B (1975)
Immune responses to mycobacterium leprae in man
J Oslo City Hosp, 25 (1), 3-24
PubMed 1092818

Myrvang B (1975)
Immune responses to Mycobacterium leprae in man
Universitetet i Oslo, Institutt for eksperimentell medisinsk forskning, Oslo, 1 b. [Flere pag.]
BIBSYS 000329983

Publications 1974

GODAL T, MYRVANG B, STANFORD JL, SAMUEL DR (1974)
RECENT ADVANCES IN IMMUNOLOGY OF LEPROSY WITH SPECIAL REFERENCE TO NEW APPROACHES IN IMMUNOPROPHYLAXIS
Bull. Inst. Pasteur, 72 (3), 273-310

Myrvang B (1974)
Immune responsiveness to Mycobacterium leprae of healthy humans. Application of the leucocyte migration inhibition test
Acta Pathol Microbiol Scand B Microbiol Immunol, 82B (5), 707-14
DOI 10.1111/j.1699-0463.1974.tb00239.x, PubMed 4611138

Myrvang B, Feek CM, Godal T (1974)
Antimycobacterial antibodies in sera from patients throughout the clinico-pathological disease spectrum of leprosy
Acta Pathol Microbiol Scand B Microbiol Immunol, 82B (5), 701-6
DOI 10.1111/j.1699-0463.1974.tb00238.x, PubMed 4215284

Publications 1973

Godal T, Myrvang B, Samuel DR (1973)
[Leprosy as an immunological model]
Tidsskr Nor Laegeforen, 93 (4), 217-22
PubMed 4570661

Godal T, Myrvang B, Samuel DR, Ross WF, Lofgren M (1973)
Mechanism of "reactions" in borderline tuberculoid (BT) leprosy. A preliminary report
Acta Pathol Microbiol Scand Suppl, 236 (0), 45-53
PubMed 4602874

Myrvang B (1973)
The immunological spectrum of leprosy
Ethiop Med J, 11 (2), 188-9
PubMed 4596876

Myrvang B, Godal T, Feek CM, Ridley DS, Samuel DR (1973)
Immune response to Mycobacterium leprae in indeterminate leprosy patients
Acta Pathol Microbiol Scand B Microbiol Immunol, 81 (5), 615-20
DOI 10.1111/j.1699-0463.1973.tb02251.x, PubMed 4209177

Myrvang B, Godal T, Ridley DS, Fröland SS, Song YK (1973)
Immune responsiveness to Mycobacterium leprae and other mycobacterial antigens throughout the clinical and histopathological spectrum of leprosy
Clin Exp Immunol, 14 (4), 541-53
PubMed 4583777

Samuel DR, Godal T, Myrvang B, Song YK (1973)
Behavior of Mycobacterium leprae in human macrophages in vitro
Infect Immun, 8 (3), 446-9
DOI 10.1128/iai.8.3.446-449.1973, PubMed 4581011

Thorsby E, Godal T, Myrvang B (1973)
HL-A antigens and susceptibility to diseases. II. Leprosy
Tissue Antigens, 3 (5), 373-7
DOI 10.1111/j.1399-0039.1973.tb00506.x, PubMed 4771178

Publications 1972

Godal T, Myrvang B, Froland SS, Shao J, Melaku G (1972)
Evidence that the mechanism of immunological tolerance ("central failure") is operative in the lack of host resistance in lepromatous leprosy
Scand J Immunol, 1 (4), 311-21
DOI 10.1111/j.1365-3083.1972.tb03296.x, PubMed 4590279

Publications 1971

Godal T, Myklestad B, Samuel DR, Myrvang B (1971)
Characterization of the cellular immune defect in lepromatous leprosy: a specific lack of circulating Mycobacterium leprae-reactive lymphocytes
Clin Exp Immunol, 9 (6), 821-31
PubMed 4945738

Sudarsanam A, Grabosz J, Myklestad B, Myrvang B, Harboe M (1971)
Experimental Arthus reactions using the same antigen in soluble and corpuscular form
Afr J Med Sci, 2 (4), 319-28
PubMed 4255853